BIIB - Biogen - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

BIIB is currently covered by 30 analysts with an average price target of $178.22. This is a potential upside of $50.72 (39.78%) from yesterday's end of day stock price of $127.5.

Biogen's activity chart (see below) currently has 955 price targets and 813 ratings on display. The stock rating distribution of BIIB is 71.71% BUY and 28.29% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 59.04% with an average time for these price targets to be met of 217.37 days.

Highest price target for BIIB is $292, Lowest price target is $115, average price target is $209.79.

Most recent stock forecast was given by BRIAN ABRAHAMS from RBC on 26-Jun-2025. First documented stock forecast 09-Sep-2010.

Overview

BiogenĀ  is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.

Portfolio

Biogen offers a diverse portfolio of therapies targeting various neurological conditions.

For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.

Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.

In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.

Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.

History

Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.

Currently out of the existing stock ratings of BIIB, 109 are a BUY (71.71%), 43 are a HOLD (28.29%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$213

$78.79 (58.71%)

$213

18 days ago
(26-Jun-2025)

39/68 (57.35%)

$86.92 (68.94%)

121

Buy

$187

$52.79 (39.33%)

$187

19 days ago
(25-Jun-2025)

9/22 (40.91%)

$60.08 (47.34%)

260

Hold

1 months 3 days ago
(11-Jun-2025)

7/32 (21.88%)

$112.06 (70.95%)

255

Hold

$121

$-13.21 (-9.84%)

$205

1 months 3 days ago
(11-Jun-2025)

25/28 (89.29%)

$-11.31 (-8.55%)

195

Buy

$169

$34.79 (25.92%)

$207

2 months 8 days ago
(06-May-2025)

23/35 (65.71%)

$51.79 (44.19%)

130

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BIIB (Biogen) average time for price targets to be met?

On average it took 217.37 days on average for the stock forecasts to be realized with a an average price target met ratio 59.04

Which analyst has the current highest performing score on BIIB (Biogen) with a proven track record?

MARC GOODMAN

Which analyst has the most public recommendations on BIIB (Biogen)?

Marc Goodman works at LEERINK and has 9 price targets and 7 ratings on BIIB

Which analyst is the currently most bullish on BIIB (Biogen)?

Ian Somaiya with highest potential upside - $268.79

Which analyst is the currently most reserved on BIIB (Biogen)?

Christopher Raymond with lowest potential downside - -$19.21

Biogen in the News

Biogen sees negative Q2 impact from IPR&D, milestone expenses

[Q2 Second Quarter Profits Stock Trading Chart 3D Background] filo * Biogen said it will incur a $46M charge in its Q2 results leading to a ($0.26) impact in its GAAP and non-GAAP EPS due to acquired in-process research and development (IPR&D), upfront, and milestone expenses. * The biotech said [https://seekingalpha.com/filing/10171292] it began listing those...

Q1 2025 Royalty Pharma PLC Earnings Call

Participants George Grofik; Senior Vice President and Head of Investor Relations & Communications; Royalty Pharma PLC Pablo Legorreta; Chairman of the Board, Chief Executive Officer; Royalty Pharma PLC Marshall Urist; Executive Vice President – Research and Investments; Royalty Pharma PLC Terrance Coyne; Chief Financial Officer, Executive Vice President; Royalty Pharma PLC Christopher Hite; Vice Chairman,...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?